Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Materiovigilance After Urinary Incontinence or Prolapse Surgery

NCT03052985 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2017-02-14
Last updated
2023-09-21

Condition(s) studied

Pelvic Organ ProlapseRectal ProlapseUrinary Stress Incontinence

Investigational drug(s) / intervention(s)

urinary incontinence, pelvic organ or rectal prolapse surgery

urinary incontinence, pelvic organ or rectal prolapse surgery: The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh

Study summary

Observatory of Materiovigilance After Surgery of Urinary Incontinence or Prolapse in Women Implantable medical devices (meshes) used in pelvic organ prolapse surgery (genital prolapse, rectal prolapse), or incontinence surgery may be source of severe complications.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Operated for urinary incontinence, pelvic organ prolapse, or rectal prolapse in one of the centres participating in the observatory * 18 years old or more.

Primary outcome measure(s)

  • Incidence of severe complications — 10 years
    Grade III or more according to Clavien-Dindo classification

Trial sites (31)

FacilityCityRegionStatus
Centre l'Avancée - Clinique Axium Aix-en-Provence France
C.H.U. d'Angers Angers France
CHRU de Besançon Besançon France
Centre Hospitalier de Béthune Béthune France
CHU de Bordeaux Bordeaux France
CHU Caen Caen France
Centre Hospitalier Camille Guérin Châtellerault France
Hôpital Antoine-Béclère Clamart France
Chu Estaing Clermont-Ferrand France
Centre Hospitalier de Dunkerque Dunkirk France
Polyclinique d'Hénin-Beaumont Hénin-Beaumont France
Hopital La Rochelle- Ré- Aunis La Rochelle France
CHU Lille Lille France
Hôpital St Vincent De Paul Lille France
CHU de Limoges Limoges France
Hospices Civils de Lyon Lyon France
Clinique BEAUSOLEIL Montpellier France
CHRU de NANCY Nancy France
CHU Nantes Nantes France
CHRU Carémeau Nîmes France
La Pitié-Salpêtrière Paris France
Hôpital Bichat Paris France
Groupe Hospitalier Diaconesses Croix Saint-Simon Paris France
Centre briochin d'Urologie Plérin France
CHI Poissy-St-Germain Poissy France
CHU de Poitiers Poitiers France
CHU de Reims Reims France
CHU Strasbourg Strasbourg France
Hopital Foch Suresnes France
Clinique UROVAR Toulon France
CHU de Toulouse Toulouse France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03052985 on ClinicalTrials.gov ↗ ← All trials in France